Do DHCR7 rs12785878 GG and CYP2R1 rs10741657 AG lower vitamin D status?

Genetic variations in key metabolic pathway genes can significantly compromise systemic vitamin D status. Specifically, polymorphisms in the DHCR7 and CYP2R1 genes alter the synthesis and processing of vitamin D at both the cutaneous and hepatic levels.

Cutaneous synthesis pathway (DHCR7)

• The DHCR7 rs12785878 GG genotype acts as a metabolic gatekeeper in the skin. The risk G allele is associated with increased activity of 7-dehydrocholesterol reductase, the enzyme that converts 7-dehydrocholesterol (7-DHC) to cholesterol.
• This up-regulation shunts the precursor 7-DHC away from UVB-mediated conversion to previtamin D3 in the epidermis. This pathway shift reduces the substrate pool available for cutaneous vitamin D synthesis, resulting in lower circulating 25(OH)D levels.

Hepatic hydroxylation pathway (CYP2R1)

• The CYP2R1 rs10741657 AG genotype is a regulatory promoter variant that directly modulates gene transcription. The presence of the G allele decreases hepatic CYP2R1 expression levels.
• Decreased expression limits the abundance of the active hepatic 25-hydroxylase enzyme. This directly reduces the rate-limiting conversion of dietary or cutaneously derived vitamin D to its primary circulating form, 25-hydroxyvitamin D [25(OH)D], and can blunt the systemic response to oral cholecalciferol supplementation.

Bottom line

• The DHCR7 rs12785878 GG and CYP2R1 rs10741657 AG genotypes are key genetic determinants of lower vitamin D status, operating through distinct upstream mechanisms: GG shunts cutaneous precursors away from vitamin D synthesis, while AG reduces hepatic conversion capacity by downregulating 25-hydroxylase expression.